DS 1123Alternative Names: DS-1123; DS-1123a
Latest Information Update: 26 Feb 2016
At a glance
- Originator Daiichi Sankyo Company
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Jan 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV) (NCT02690337)